

Cont
a1
5. (Amended) A method according to claim 1, wherein the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., is ecarin. 163

6. (Amended) A method according to claim 1, wherein the chromogenic substrate dissociable by active meizothrombin or Mtdesfgl, resp., releases p-nitroanilin under dissociation, and the light absorption measurement is performed at 405 nm. 162

7. (Amended) A method according to claim 1, wherein in step c) a first absorption or emission measurement after 0 - 100 s, preferably 0 - 50, most preferably 5 - 15 s, and a second one after another 10 - 1,000 s, preferably 50 - 500s, most preferably 150 - 300 s, measured from the addition of the substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., are performed.

8. (Amended) A method according to claim 1, wherein the thrombin inhibitor is hirudin, a hirulog or a synthetic thrombin inhibitor. 161

11. (Amended) A test kit according to claim 9, wherein the kit components are separated from each other but provided in a single test kit package. 160

a2
12. (Amended) A test kit according to claim 9, wherein as an optional additional kit component, a solution with prothrombin is provided.

Cont
a 2

B) the reduction of the light absorption or light emission per time unit is determined for each prospective thrombin inhibitor and compared to the light absorption or light emission per time unit of a given, preferably identical concentration of hirudin determined under identical conditions,

C) those prospective thrombin inhibitors are selected the reduction of the light absorption or light emission of which per time unit corresponds to at least 10 % of the corresponding reduction when hirudin is used.